ArticlePragmatic and observational research2025
Evaluation of Disease Modifying Therapies and Prognostic Factors Affecting Multiple Sclerosis Progression in a Local Centre of Hong Kong.
Article in Pragmatic and observational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Multiple sclerosis (MS) is a major demyelinating disease causing disability in young adults. Scarce data exists on the clinical benefits and persistence of disease modifying therapies (DMTs) amongst our local population. The primary aim of this study was to investigate the effectiveness, tolerability and discontinuation pattern of various DMTs amongst Hong Kong patients. Methods: This was a retrospective study of adult MS patients treated in a tertiary hospital in Hong Kong from 1st December 2012 to 30th November 2022. Demographic, clinical and radiological characteristics were retrieved. Results: A total of 103 patients were analysed. Interferons (annualised relapse rate (ARR) reduction 0.492, p <0.001) and fingolimod (ARR reduction 0.557, p = 0.038) had significant ARR reductions in our cohort. Overall treatment persistence were comparable, but teriflunomide had more discontinuation due to side effects and/or intolerance (hazard ratio (HR) 7.50, p = 0.029). Baseline Expanded Disability Status Score (EDSS) more than or equal to 4.0 (odds ratio (OR) 4.56, p = 0.045), and presence of brainstem lesions on magnetic resonance imaging (OR 3.15, p = 0.039) were associated with greater disability progression, while visual onset symptoms at diagnosis (OR 0.14, p = 0.007) were associated with lower risk. Discussion: This study illustrated the complexity of managing MS patients. Patients' clinical characteristics, disease activity, risk appetite and treatment side effects should be taken in consideration to reach an informed decision on the use of DMTs in our local MS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.